Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
PMCID: PMC4885833
$45.00 Original price was: $45.00.$34.99Current price is: $34.99
doi: 10.1111/tbj.2009.16.issue-1 20 PetrekJASenieRTPetersMRosenPP
New England Journal of Medicine: Retatrutide Phase 2 trial results - The landmark study establishing retatrutide efficacy and safety across multiple dose groups New England Journal of Medicine: STEP 1 semaglutide trial results - The pivotal trial demonstrating semaglutide 2.4 mg weight loss efficacy ClinicalTrials.gov: Retatrutide TRIUMPH program - Current status and details of all ongoing Phase 3 retatrutide trials FDA prescribing information for Wegovy (semaglutide 2.4 mg) - Complete approved labeling including dosing, safety, and clinical data New England Journal of Medicine: SELECT cardiovascular outcomes trial - The trial demonstrating semaglutide 20% reduction in major cardiovascular events These primary sources should be the foundation for any serious evaluation of either compound
10.1016/j.jmig.2007.06.003 136 YuL.SaileK.SwartzC
Another component that Wegovy utilizes is its ability to keep the liver from creating too much sugar and producing fat deposits in the tissue
:max_bytes(150000):strip_icc()/Simple-7-Day-GLP-1-Friendly-Meal-Plan-for-Beginners-Created-by-a-Dietitian-69f3d02b6c2c41928135df7f0c417552.jpg)
